Tony Busby

Tony Busby is an account manager with Legend Biotech, the manufacturer of CARVYKTI®, a CAR-T cell therapy for patients with relapsed refractory multiple myeloma. His career has been shaped by a lifelong commitment to improving patient outcomes and expanding access to innovative therapies. After spending 23 years with Novo Nordisk as a regional education manager, supporting cardiovascular, diabetes, and obesity care, Tony’s professional path took a deeply personal turn in 2020 when his daughter, Breya, was diagnosed with acute lymphoblastic leukemia (ALL). Witnessing her battle with cancer and the life-saving impact of CAR-T therapy ignited a passion for advancing awareness and access to breakthrough treatments for patients facing life-threatening diseases. Following Breya’s successful CAR-T treatment, Tony transitioned into oncology/hematology with Sanofi, where he focused on bone marrow transplantation (BMT) and graft-versus-host disease (GVHD), gaining valuable experience supporting